Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:37:55 EDT Sun 28 Apr 2024
Enter Symbol
or Name
USA
CA



Z:CANF - CAN FITE BIOPHARMA LTD SPON ADS EACH REP 300 ORD SHS(POST SP - http://www.canfite.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CANF - Z0.11.68·2.190.11.98+0.031.58.713202.00  2.01  1.913.33  1.705117:37:26Apr 2515 min RT 2¢

Recent Trades - Last 10 of 20
Time ETExPriceChangeVolume
17:37:26Z1.83-0.091
15:59:54Z1.960.0419
15:52:03Z1.960.041
15:50:08Z1.960.041
15:45:52Z1.950.03100
15:00:35Z1.97030.050340
14:25:43Z2.000.085
13:46:10Z1.95990.0399100
12:42:33Z1.960.0456
12:23:33Z1.960.0425

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 07:00U:CANFNews ReleaseLong-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
2024-04-15 07:00U:CANFNews ReleaseCan-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
2024-04-03 07:00U:CANFNews ReleaseCan-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
2024-04-01 07:01U:CANFNews ReleaseCan-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV
2024-03-28 07:00U:CANFNews ReleaseCan-Fite Reports 2023 Financial Results and Clinical Update
2024-03-11 07:00U:CANFNews ReleaseNamodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
2024-02-28 07:00U:CANFNews ReleaseCan-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
2024-01-30 07:00U:CANFNews ReleaseCan-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
2024-01-29 07:00U:CANFNews ReleaseCan-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
2023-12-20 07:00U:CANFNews ReleaseThe Anti-Obesity Effect of Can-Fite ¢ € ™s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
2023-12-18 07:00U:CANFNews ReleaseCan-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
2023-12-04 07:00U:CANFNews ReleaseCan-Fite ¢ € ™s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
2023-11-30 07:00U:CANFNews ReleaseCan-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
2023-11-21 13:53U:CANFNews ReleaseCan-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
2023-11-21 07:00U:CANFNews ReleaseCan-Fite: Complete Response and 6.9 Years ‚  Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
2023-11-01 07:00U:CANFNews ReleaseCan-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
2023-10-30 07:00U:CANFNews ReleaseCan Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
2023-10-26 07:00U:CANFNews ReleaseCan-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
2023-10-09 07:00U:CANFNews ReleaseCan-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
2023-09-27 07:00U:CANFNews ReleaseCan-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)